Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, develops, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based p… Read more
Medipharm Labs Corp (MEDIF) - Total Assets
Latest total assets as of September 2025: $46.60 Million USD
Based on the latest financial reports, Medipharm Labs Corp (MEDIF) holds total assets worth $46.60 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medipharm Labs Corp - Total Assets Trend (2016–2024)
This chart illustrates how Medipharm Labs Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medipharm Labs Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Medipharm Labs Corp's total assets of $46.60 Million consist of 61.6% current assets and 38.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.8% |
| Accounts Receivable | $6.88 Million | 12.8% |
| Inventory | $8.71 Million | 16.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $854.00K | 1.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Medipharm Labs Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medipharm Labs Corp's current assets represent 61.6% of total assets in 2024, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 21.8% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 16.2% of total assets.
Medipharm Labs Corp Competitors by Total Assets
Key competitors of Medipharm Labs Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Medipharm Labs Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Medipharm Labs Corp generates 0.78x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medipharm Labs Corp is currently not profitable relative to its asset base.
Medipharm Labs Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | 3.21 | 3.36 |
| Quick Ratio | 2.27 | 2.36 | 2.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.19 Million | $ 23.81 Million | $ 57.28 Million |
Medipharm Labs Corp - Advanced Valuation Insights
This section examines the relationship between Medipharm Labs Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.79 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -16.0% |
| Total Assets | $53.73 Million |
| Market Capitalization | $22.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medipharm Labs Corp's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medipharm Labs Corp's assets decreased by 16.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medipharm Labs Corp (2016–2024)
The table below shows the annual total assets of Medipharm Labs Corp from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $53.73 Million | -15.96% |
| 2023-12-31 | $63.94 Million | -2.38% |
| 2022-12-31 | $65.50 Million | -29.09% |
| 2021-12-31 | $92.36 Million | -21.88% |
| 2020-12-31 | $118.23 Million | -29.97% |
| 2019-12-31 | $168.83 Million | +36520.34% |
| 2018-12-31 | $461.03K | +15.26% |
| 2017-12-31 | $400.00K | +52.56% |
| 2016-12-31 | $262.19K | -- |